R&D Areas | Transplantation

It is important that any post-transplantation complications, such as rejection, be identified as early as possible so that appropriate therapy can be initiated. Currently definite identification of such complications involves the analysis of biopsies, which is not suitable for repetitive monitoring. Studies of the levels of many individual proteins found in more accessible body fluids have been undertaken to determine their utility as early biomarkers, but no single marker has sufficient diagnostic sensitivity or specificity to be of practical use. Whole proteome analysis of body fluids, however, has the potential of identifying patterns of biomarkers.

Mosaiques´ CE-MS technology is the most promising of the techniques and has already enabled the identification of a specific peptide pattern that can distinguish rejection in kidney transplant patients or is capable of the early detection of Graft-versus-Host Disease, a severe complication during allogeneic hematopoietic stem cell transplantation (aHSCT).